Rankings
Publications
Search Publications
Cited-By Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Login
Register
Home
Publications
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
Home
Publications
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
PC
Paul Covington
Paul Covington
Ronald Christopher
Ronald Christopher
MD
Michael Davenport
Michael Davenport
PF
Penny Fleck
Penny Fleck
QM
Qais A. Mekki
Qais A. Mekki
EW
Elisabeth R. Wann
Elisabeth R. Wann
AK
Aziz Karim
Aziz Karim
Publisher Website
Google Scholar
Add to Library
Cite
Download
Share
Download
1 March 2008
journal article
research article
Published by
Elsevier
in
Clinical Therapeutics
Vol. 30
(3)
,
499-512
https://doi.org/10.1016/j.clinthera.2008.03.004
Abstract
No abstract available
Keywords
TYPE 2 DIABETES
ALOGLIPTIN
GLUCAGONLIKE PEPTIDE-1
DIPEPTIDYL PEPTIDASE-4
INCRETIN
SYR-322
Cited by 126 articles